EC approves Novartis ’ breast cancer drug Kisqali

Swiss drugmaker Novartis ’ Kisqali (ribociclib) has received approval from the European Commission (EC) as a first-line treatment for advanced breast cancer.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news